|
Synonyms: ADCT-402 | ADCT402 | loncastuximab tesirine-lpyl | RB4v1.2-SG-3249 | Zynlonta®
loncastuximab tesirine is an approved drug (FDA (2021), EMA (2022))
Compound class:
Antibody
Comment: Loncastuximab tesirine (ADCT-402) is an antibody-drug conjugate that delivers the toxic payload teserine (pyrrolobenzodiazepine dimer SG3249, which acts as a DNA alkylating and cross-linking agent [4]) to CD19-expressing B cells [6]. The linker contains a valine-alanine dipeptide bridge that is specifically recognized and cleaved by cathepsin B (CTSB; which is highly expressed by tumour cells) [3,5].
|
Classification ![]() |
|
| Compound class | Antibody |
| Approved drug? | Yes. China NMPA (2024) | EU EMA (2022) | US FDA (2021) |
International Nonproprietary Names ![]() |
|
| INN number | INN |
| 10586 | loncastuximab tesirine |
Synonyms ![]() |
| ADCT-402 | ADCT402 | loncastuximab tesirine-lpyl | RB4v1.2-SG-3249 | Zynlonta® |
Database Links ![]() |
|
| Specialist databases | |
| IMGT/mAb-DB | 749 |
| Other databases | |
| GtoPdb PubChem SID | 441604893 |
| Search PubMed clinical trials | loncastuximab tesirine |
| Search PubMed titles | loncastuximab tesirine |
| Search PubMed titles/abstracts | loncastuximab tesirine |